Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
Cancer Research
|
December 18, 2004
Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM
Ian Hickson, Yan Zhao, Caroline J Richardson, et al.
Cancer Research
|
April 23, 2009
Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin
Trevor Hay, James R Matthews, Lucie Pietzka, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 27, 2008
Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase
Keith A Menear, Claire Adcock, Francisco Cuenca Alonso, et al.
Nature
|
April 15, 2005
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J Lord, et al.
Journal of Medicinal Chemistry
|
March 23, 2011
5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2)
Peter T Sunderland, Esther C Y Woon, Archana Dhami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2008
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin
Bastiaan Evers, Rinske Drost, Eva Schut, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 8, 2009
Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR
Keith A Menear, Sylvie Gomez, Karine Malagu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 31, 2008
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, et al.
Cancer Discovery
|
October 30, 2012
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors
Janneke E Jaspers, Ariena Kersbergen, Ute Boon, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 20, 2005
Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase
Vincent M Loh, Xiao-ling Cockcroft, Krystyna J Dillon, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
Cancer Research
|
December 18, 2004
Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM
Ian Hickson, Yan Zhao, Caroline J Richardson, et al.
Cancer Research
|
April 23, 2009
Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin
Trevor Hay, James R Matthews, Lucie Pietzka, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 27, 2008
Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase
Keith A Menear, Claire Adcock, Francisco Cuenca Alonso, et al.
Nature
|
April 15, 2005
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J Lord, et al.
Journal of Medicinal Chemistry
|
March 23, 2011
5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2)
Peter T Sunderland, Esther C Y Woon, Archana Dhami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2008
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin
Bastiaan Evers, Rinske Drost, Eva Schut, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 8, 2009
Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR
Keith A Menear, Sylvie Gomez, Karine Malagu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 31, 2008
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, et al.
Cancer Discovery
|
October 30, 2012
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors
Janneke E Jaspers, Ariena Kersbergen, Ute Boon, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 20, 2005
Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase
Vincent M Loh, Xiao-ling Cockcroft, Krystyna J Dillon, et al.
Page
of 3